$XBI $87.32 | -3.34%
$AGLE -6.5% Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD source
$GILD -0.7% FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies source
$EDIT -4.3% Sellas Life Sciences - SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study.
$SEEL -4.7% Sellas Life Sciences - SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study.
$MRNA -0.5% Moderna - Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates.
$CRIS -8.3% Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948).
$ETON -10.4% Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection.
$KRYS -0.3% Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study.
$SCPH -14.8% scPharmaceuticals Inc. Announces Resubmission of FUROSCIX® New Drug Application.
$BCYC -38.7% Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting.
$SSPI -2.6% Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim.
$MNOV -0.7% MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia.
$GRCL -11.3% Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL.
$IMV +6.6% IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting.
$SURF -2.2% Surface Oncology Presents New SRF388 Data at the American Association for Cancer Research (AACR) Annual Meeting 2022.
$SEEL -4.7% Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenixus AG for SLS-002 (Intranasal Racemic Ketamine Program), All Future Success and Commercial Based Milestones and the Change of Control Fee.
$ALZN -6.3% Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s.
$ARDX -5.4% Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor.
$ORTX -3.6% Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy.
$BTNX -0.2% & MTNB +23.3% BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines.
$CLSN -9.7% Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules.
Posted by DV/JM